ArticleBrain and behavior2025
Association Between Hypoxia-Inducible Factor-1α and Neurological Diseases: A Bidirectional Two-Sample Mendelian Randomization Analysis.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Mechanistic investigation of HMGB1 in an in vitro model of the trigeminovascular system under migraine-like conditions.The journal of headache and pain · 2026Article
- Altered expressions of CGRP, SULT1A1, HMGB1, and HIF-1α in the trigeminal ganglion in medication overuse headache in female rats.The journal of headache and pain · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrevious studies have suggested that hypoxia-inducible factor 1-α (HIF-1α) exerted multiple effects on different central nervous system disorders. However, it is still uncertain whether plasma HIF-1α can be a causal indicator for the relevant diseases. This study aimed to test the causality relationship between plasma HIF-1α and neurological diseases, including cerebrovascular diseases, migraines, and neurodegenerative diseases with a Mendelian randomization (MR) method.
methodsSingle-nucleotide polymorphisms (SNPs) genetically representing plasma HIF-1α were screened as instrumental variables (IVs). Summary-level data for neurological disorder from genome-wide association studies (GWAS) were identified as outcomes. The causal effects between the IVs and outcomes were determined via the major analysis of inverse-variance-weighted (IVW) method. The reverse causal direction was also performed to investigate the possibility of reverse causation.
resultsThe findings revealed that plasma HIF-1α was identified to be genetically associated with cardioembolic stroke (CES) (OR = 0.885; 95% confidence interval [CI] = 0.796-0.985, p = 0.026), migraine (OR = 0.941, 95% CI = 0.888-0.998, p = 0.041), and drug-induced migraine without aura (MOA) (OR = 0.586, 95% CI = 0.375-0.916, p = 0.019). There was no association identified in plasma HIF-1α with subarachnoid hemorrhage (SAH), other stroke and migraine subtype, and neurodegenerative disorders. The reverse-MR analysis revealed that the above-stated neurological diseases did not have a causal effect on plasma HIF-1α levels. Sensitivity and validation analyses support that the above results are stable.
conclusionsOur research indicated that plasma HIF-1α may have a causal effect on the risk of CES, migraine and drug-induced MOA, providing new insights for those disease prevention and therapeutic approaches.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.